Posted on 11/02/2010 in Pharmaceutical Company Financials Biogen Idec has unveiled its financial results for 2009, revealing a revenue rise of seven per cent for the full year.
During the 12-month period, the firm's revenues increased to $4.4 billion (2.8 billion pounds), a rise the company attributes to the continued growth of its treatment TYSABRI (natalizumab).
Sales of the therapy grew by 32 per cent to $776 million, while AVONEX (interferon beta-1a) revenues rose by five per cent to a total of $2.3 billion.
Meanwhile, revenues for the fourth-quarter reached $1.1 billion - up by five per cent on figures from the final quarter of 2008.
"We recorded our sixth consecutive year of double-digit EPS growth, TYSABRI became [our] third blockbuster product and we advanced two programmes into registrational trials," said James Mullen, Biogen Idec's president and chief executive officer.
In other Biogen Idec news, the organisation this week announced that it has recruited two experts in multiple sclerosis for the strengthening of its research and development in the area. Other news stories from 11/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
